An in vivo high-throughput screening approach targeting the type IV secretion system component VirB8 identified inhibitors of Brucella abortus 2308 proliferation.
about
Type IV secretion system of Brucella spp. and its effectorsBacterial Type IV secretion systems: versatile virulence machinesStructural analysis and inhibition of TraE from the pKM101 type IV secretion systemCharacterization of transcription factors that regulate the type IV secretion system and riboflavin biosynthesis in Wolbachia of Brugia malayiDiversity in genetic in vivo methods for protein-protein interaction studies: from the yeast two-hybrid system to the mammalian split-luciferase system.Endoplasmic reticulum protein ERp46 in renal cell carcinomaSystems biology approach predicts antibody signature associated with Brucella melitensis infection in humans.Pathogenesis and immunobiology of brucellosis: review of Brucella-host interactionsSerial kinetics of the antibody response against the complete Brucella melitensis ORFeome in focal vertebral brucellosisPeptidomimetic Small Molecules Disrupt Type IV Secretion System Activity in Diverse Bacterial Pathogens.Analysis of Membrane Protein Interactions with a Bacterial Adenylate Cyclase-Based Two-Hybrid (BACTH) Technique.Structural Insight into How Bacteria Prevent Interference between Multiple Divergent Type IV Secretion Systems.Protein-Protein Interaction: Bacterial Two-Hybrid.A lysozyme-like protein in Brucella abortus is involved in the early stages of intracellular replication.The expanding bacterial type IV secretion lexicon.Bloodstream form pre-adaptation to the tsetse fly in Trypanosoma brucei.Potential of known and short prokaryotic protein motifs as a basis for novel peptide-based antibacterial therapeutics: a computational survey.Ecology and evolution as targets: the need for novel eco-evo drugs and strategies to fight antibiotic resistance.Brucellosis and type IV secretion.The ins and outs of Mycobacterium tuberculosis protein export.Bacterial surface appendages as targets for novel antibacterial therapeutics.Anti-virulence Strategies to Target Bacterial Infections.Strategies to Block Bacterial Pathogenesis by Interference with Motility and Chemotaxis.The Mosaic Type IV Secretion SystemsThe Rickettsia type IV secretion system: unrealized complexity mired by gene family expansion.Novel Role for PilNO in Type IV Pilus Retraction Revealed by Alignment Subcomplex Mutations2- and 3-substituted imidazo[1,2-a]pyrazines as inhibitors of bacterial type IV secretion.A novel strategy to target bacterial virulence.Fragment-based screening identifies novel targets for inhibitors of conjugative transfer of antimicrobial resistance by plasmid pKM101.Conjugation Inhibitors and Their Potential Use to Prevent Dissemination of Antibiotic Resistance Genes in Bacteria.Type IV secretion in Gram-negative and Gram-positive bacteria.The type IV secretion system core component VirB8 interacts via the β1-strand with VirB10.Monomer-to-dimer transition of Brucella suis type IV secretion system component VirB8 induces conformational changes.
P2860
Q26777118-E7411820-F113-4738-9B96-887EC732D20AQ27027905-40BB2A01-230D-4447-BF29-E7DB0CBA67D8Q27728073-04330ACD-C937-4EAB-9CCE-8FF754FB4D4EQ28484257-CCDE110E-5F80-4CF9-A4B2-4648939F3430Q34280594-CC07F03B-FFC4-43E9-BC82-6AB5440FD8EAQ35110644-4C7D9273-F3CB-4D6A-95D0-E3A5A65EF0FDQ35296643-5855D447-0BEA-4367-A104-D77007CFAD27Q35669016-ED134845-A17D-4C9B-B6EA-133511A794ADQ35807148-251ECCA9-7063-4957-B903-59D08680C46EQ36000469-B6A998CE-4EF7-4156-8204-7FF4614373C4Q36332279-AD4B7250-6012-45C9-A40D-AC5F3E6B1AD9Q36364607-1AE74A2F-C1D8-4B3B-B1BE-3459999D234FQ36414144-34EE0388-24C8-4F9B-8122-CA44A2AC00B1Q36646792-5AA81302-7A12-40F3-99FB-0F55A5FE3BF4Q37275377-714F9D83-EBE6-4F63-BBFC-DD6309D984C7Q37307047-66D1D110-4928-4CCF-A1F8-FD67AAAE123BQ37498015-1F195C4F-7693-43F1-ADE5-AB11705B45EFQ37876027-FE808A17-CEBB-4468-B660-8CF70BD3448DQ37970703-1E817855-01BE-4D57-A2CC-B8C86B518FB7Q37970858-49831F75-CF1F-4FF1-BEEF-E0E02DA2AFC5Q38243219-D11195CE-BE5A-4536-B049-6789A1FCDDF0Q38760476-A31122FE-A1D6-4BDE-9921-948F5D117D69Q38783540-1C5CC711-9B59-464B-9C90-3628CB72A294Q38979499-312B1F7F-B930-4227-A94B-F8558FB1783FQ40982842-9BC1306D-9FF3-400F-AEEC-44161698ACA3Q41007265-5F187A30-890D-47B7-815B-3005231CA7A3Q43161347-E068F23C-4BFC-4BCD-A527-8CB04CA08C20Q44185216-BCBC0DAE-8446-47C8-B0B3-A8EB6CFF3E14Q47095102-5ACDF05A-5FDB-4131-83C0-A90C9AC1BB02Q47098910-EB5D44CD-9909-4EB3-A665-EA7632773FDFQ47299307-D4255575-5850-49E8-B4FA-A3F58A5B0B0EQ48000978-1C0FEB37-C6F9-40C9-8A44-0BC3E70CCF37Q48194465-5FD10789-BF06-45E6-9130-9BE38D1B4E25
P2860
An in vivo high-throughput screening approach targeting the type IV secretion system component VirB8 identified inhibitors of Brucella abortus 2308 proliferation.
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
An in vivo high-throughput scr ...... la abortus 2308 proliferation.
@ast
An in vivo high-throughput scr ...... la abortus 2308 proliferation.
@en
An in vivo high-throughput scr ...... la abortus 2308 proliferation.
@nl
type
label
An in vivo high-throughput scr ...... la abortus 2308 proliferation.
@ast
An in vivo high-throughput scr ...... la abortus 2308 proliferation.
@en
An in vivo high-throughput scr ...... la abortus 2308 proliferation.
@nl
prefLabel
An in vivo high-throughput scr ...... la abortus 2308 proliferation.
@ast
An in vivo high-throughput scr ...... la abortus 2308 proliferation.
@en
An in vivo high-throughput scr ...... la abortus 2308 proliferation.
@nl
P2093
P2860
P356
P1476
An in vivo high-throughput scr ...... lla abortus 2308 proliferation
@en
P2093
Andreas den Hartigh
Athanasios Paschos
Christian Baron
Durga Sivanesan
Mark A Smith
Vidya L Atluri
P2860
P304
P356
10.1128/IAI.00993-10
P407
P577
2010-12-20T00:00:00Z